# JAGX · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** JAGX  
**Sources:** 24  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-jagx-catalysts-narrative-risks-4679

---

## Company Snapshot (as of 2026-10-02/03)

Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company that develops plant-derived (crofelemer-based) prescription and non-prescription medicines for gastrointestinal conditions in people and animals, operating through Animal Health and Human Health segments [[21]](https://stockanalysis.com/stocks/jagx/), [[22]](https://stocktwits.com/symbol/JAGX). It was founded by Lisa A. Conte and is headquartered in San Francisco, CA [[22]](https://stocktwits.com/symbol/JAGX). As of the Oct 2 close, the stock traded at ~$3.66 (down 7.34%) with a market cap of ~$1.90M, and the 52-week range stretched from $2.35 to ~$1,268 [[20]](https://finance.yahoo.com/quote/JAGX/), [[21]](https://stockanalysis.com/stocks/jagx/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-jagx-catalysts-narrative-risks-4679 (free to sign up)._